Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832930 | 0.84 | PPARA (0.45) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL18614293 | 0.83 | CTSS (0.49) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL8280383 | 0.83 | CTSS (0.49) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL26115324 | 0.83 | CTSS (0.49) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL27723686 | 0.81 | CTSK (0.51) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL7280758 | 0.80 | CTSS (0.49) | CTSSCTSKCTSLCTSBACE | |
| Hydrazine SCHEMBL8410651 | 0.78 | CTSL (0.62) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL13598609 | 0.78 | CTSS (0.48) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL4424071 | 0.78 | CTSS (0.48) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL66243 | 0.78 | CTSL (0.66) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8747809-B2 | Single diastereomers of 4-fluoroglutamine and methods of their preparation and use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | GCG, FPGS, FOLH1 | CTSS 1784/4885CTSK 1895/4885CTSL 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.